Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229030 · ClinicalTrials.gov registry record · Phase 2
RZL-012 for Dercum's Disease Lipomas
A Phase 2 study of Dercum's Disease Lipomas, sponsored by Raziel Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04229030 is a Phase 2 study of Dercum's Disease Lipomas that has completed, run by Raziel Therapeutics. The registered enrollment target is 38 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04229030, a Phase 2 study of Dercum's Disease Lipomas, has completed, sponsored by Raziel Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG RZL-012
Study Locations (1)
California
- Limitless Therapeutics - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-07-30 |
| Est. Completion | 2021-02-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04229030
The ClinicalTrials.gov registry entry for NCT04229030 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Raziel Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dercum's Disease Lipomas appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04229030 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04229030 about?
NCT04229030 is a clinical study titled "RZL-012 for Dercum's Disease Lipomas". Thirty-eight (38) subjects will be included in the study. Subjects will be randomized in a ration of 1:1 to be treated with RZL-012 or placebo. Subjects will be injected with a different doses of RZL-012 according to their lipomas sizes. The total of 38 subjects will be enrolled in 3 clinical sites.
What is the current status of trial NCT04229030?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2020-07-30. Estimated completion is 2021-02-20.
What conditions does trial NCT04229030 study?
This clinical trial studies the following conditions: Dercum's Disease Lipomas.
What interventions are being tested in trial NCT04229030?
The interventions under investigation include: Vehicle (DRUG), RZL-012 (DRUG).
Who is sponsoring clinical trial NCT04229030?
This trial is sponsored by Raziel Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04229030 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.